Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Amortizatization of Intangibles: 2021-2025

Historic Amortizatization of Intangibles for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $4.6 million.

  • Janux Therapeutics' Amortizatization of Intangibles rose 59.52% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 74.68%. This contributed to the annual value of $10.6 million for FY2024, which is 37.68% up from last year.
  • As of Q3 2025, Janux Therapeutics' Amortizatization of Intangibles stood at $4.6 million, which was down 11.20% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Amortizatization of Intangibles registered a high of $5.2 million during Q2 2025, and its lowest value of $24,000 during Q1 2022.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $2.9 million (2024), whereas its average is $2.9 million.
  • Data for Janux Therapeutics' Amortizatization of Intangibles shows a peak YoY skyrocketed of 6,891.67% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Amortizatization of Intangibles stood at $58,000 in 2021, then skyrocketed by 2,127.59% to $1.3 million in 2022, then spiked by 59.52% to $2.1 million in 2023, then spiked by 42.02% to $2.9 million in 2024, then spiked by 59.52% to $4.6 million in 2025.
  • Its Amortizatization of Intangibles stands at $4.6 million for Q3 2025, versus $5.2 million for Q2 2025 and $4.2 million for Q1 2025.